COIOSDeep risk insights through multi-disciplinary research across the globe
A bunch of drawers that have numbers on them
Item confirms Peer-reviewed Added

GLP-1 receptor agonists and cancer risk in an umbrella review of 38 meta-analyses

In 48 placebo-controlled trials with 94 245 participants, GLP-1RAs showed no significant rise in overall or site-specific cancer.

This umbrella review assessed cancer risk with GLP-1 receptor agonists and tirzepatide across 38 meta-analyses from 2012 to 2026. Randomised and observational evidence were appraised separately for review quality, overlap and certainty. In 48 placebo-controlled trials with 94 245 participants, thyroid cancer showed no significant association (OR 1·37, 95% CI 0·82-2·31). Pancreatic, colorectal and breast cancer were also not significant, and overall cancer showed no increase (OR 1·05, 0·98-1·13). Observational syntheses suggested lower hepatocellular carcinoma risk (HR 0·60, 0·41-0·88), but four reviews overlapped heavily. No outcome reached high certainty, and median trial follow-up of about 70 weeks cannot address long-latency cancers.

Why it is interesting: Cancer safety evidence for increasingly used GLP-1 drugs rests on trials with a median follow-up of about 70 weeks. Reviews disagreed on thyroid and colorectal cancer mainly through comparators, pooling methods and handling of zero-event trials.

Source
Cancer Epidemiology, 20 November 2026
DOI
10.1016/j.canep.2026.103273
Type
Peer-reviewed article
Design
Umbrella review of 38 meta-analyses (2012-2026) of GLP-1RA/tirzepatide and incident cancer, with AMSTAR 2, overlap (CCA), GRADE-informed certainty and Ioannidis credibility appraisal; largest randomised set 48-50 trials, 94,245 participants, median 70 weeks
Verdict
Confirms prior evidence
Driver
Cancer
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today